Generic Pharmaceutical Trade Group Steps in to Protect Patient Access to Affordable Generic Drugs
WASHINGTON, DC (JULY 5, 2023) – The Association for Accessible Medicines (AAM), the trade association representing America’s manufacturers of generic and biosimilar medicines, today filed a lawsuit against Minnesota Attorney General Keith Ellison, requesting that the federal district court in Minnesota enjoin the Attorney General from enforcing the price-control provisions of Senate File 2744.
Each year, we look forward to hosting our members, friends, colleagues and partners for Access!, AAM’s annual meeting. Held in Orlando, Florida, this year’s conference was unique in that we also hosted the 25th Annual Meeting of the International Generic and Biosimilar Medicines Association (IGBA) in the same location, a dual experience that helped to strengthen global cooperation in our shared effort to expand patient access to more affordable generic and biosimilar medicines.
Entrepreneur and founder of the Mark Cuban Cost Plus Drug Company, PBC, Mark Cuban, sat down with our new Board Chair Christine Baeder, SVP, COO for US Generics at Teva Pharmaceuticals, to discuss his efforts to reduce #drugprices and increase competition in the drug market. #Access2023 #drugprices #patientaccess
WASHINGTON, DC (January 30, 2023) — The Association for Accessible Medicines (AAM) applauds the Centers for Medicare & Medicaid Services (CMS) for several of the recommended provisions outlined in the proposed Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024. In particular, AAM publicly commends the administration’s efforts to standardize plan choice by requiring generic drugs be placed on “generic” tiers and brand-name drugs on “brand-name” tiers.
When Desi's swollen ankle began hurting so much that he was unable to run and keep up with his friends, his parents, Jonathan and Susan of Maryland, became concerned. After several doctor visits, a rheumatologist diagnosed Desi with juvenile idiopathic arthritis (JIA), an autoimmune disease. To help manage the symptoms of JIA, Desi receives weekly injections of autoimmune suppressant medicine and daily doses of anti-inflammatory medicines.
Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. While we now have effective treatment options to help patients manage their conditions, many brand drugs come with steep price tags. Fortunately, there are more affordable generic and biosimilar treatments that reduce costs for patients and increase access to lifesaving care.
WASHINGTON D.C. (December 13, 2022) -- The Association for Accessible Medicines (AAM) commends the Centers for Medicare & Medicaid Services (CMS) for their proposal requiring generic drugs to be covered on generic tiers.
Numerous studies agree: Generics provide savings on prescription drugs. And six years into a sustained period of price deflation, many generic prices are lower than ever. But inexplicably, patients are paying more for many generics. Although the Medicare program has rules to safeguard beneficiaries, it has allowed Medicare drug plans to make changes that require patients to pay more for many generic drugs even as the prices of those drugs have fallen.
A Reference Guide for Lawmakers
With record high inflation, voters are concerned about the rising costs of goods – including life-saving medicines. AAM developed a resource for lawmakers to provide effective communications around the ever-increasing costs of medicines. This guide includes facts about generic and biosimilar medicines, the problems causing the high cost of medicine and solutions to lower drug prices for patients and their families.